

Custom Antibody Services Market? By Service (Antibody Development, Antibody Production and Purification, Antibody Fragmentation and Labeling) , By Type (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Antibodies, Others) By Source (Mice, Rabbit, Others) By Application (Oncology, Infectious Diseases, Neurology, Immunology, Cardiovascular Diseases, Others) By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Market Report | 2024-07-01 | 233 pages | Allied Market Research

AVAILABLE LICENSES:

- Cloud Access License \$2389.50
- Business User License \$5157.00
- Enterprise License \$6670.80

Report description:

Custom Antibody Services Market

The custom antibody services market was valued at \$0.6 billion in 2023 and is projected to reach \$1.4 billion by 2033, growing at a CAGR of 8.7% from 2024 to 2033.

Custom antibody services involve producing distinguished antibodies as per user requirements. The antibodies are specifically tailored for diagnostic, research, and therapeutic purposes. A key benefit of utilizing custom antibody services is the attainability of specificity in antibodies against antigens, resulting in improved & reliable experimental results. In addition, the flexibility of integrating different modifications into the antibodies attracts clients to benefit from the custom antibody services.

Increase in the popularity of personalized medicine for targeted therapies is rising the adoption of custom antibody services in the healthcare field. In addition, with surging expenditure in the pharmaceutical and biotech sectors for the strengthening of their R&D activities, the growth of the market is being driven considerably. The future of the custom antibody services market is anticipated to be redefined by recombinant technology and novel antibody trends. AI and ML algorithm are poised to assist in the

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott-international.com

www.scott-international.com

designing of antibodies and develop next-generational antibodies such as single domain antibodies, bispecific antibodies, and antibody fragments. □

However, the high cost of antibody production and extended development time hamper the growth of the custom antibody services market. In addition, the quality control measures and validation processes established for the approval of antibodies are highly rigorous and time-consuming. Efficient compliance with such standards delays the growth of the market. Contrarily, with rising investments on drug development and R&D, the custom antibody services market is anticipated to witness several lucrative growth opportunities. According to Statista, a global data and business intelligence platform, the U.S. spent an estimated amount of \$603 billion on medicine in 2022. Furthermore, pharma companies in the U.S. spend approximately 21% of their revenue on R&D activities. Such expenditures indicate a promising future for the custom antibody services market. □

Segment Review □

The custom antibody services market □ is segmented into service, type, source, application, end user, and region. On the basis of service, the market is divided into antibody development, antibody production & purification, and antibody fragmentation & labeling. As per type, it is classified □ into monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and others. Depending on source, it is categorized into mice, rabbit, and others. According to application, it is divided into oncology, infectious diseases, neurology, immunology, cardiovascular diseases, and others. By end user, it is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. □

Key Findings □

On the basis of service, the antibody development segment dominated the market in 2023. □

As per type, the monoclonal antibodies segment was the major shareholder of the market in 2023. □

Depending on source, the rabbit segment held a high share in the market in 2023. □

According to application, the infectious diseases segment accounted for a high share in the market in 2023. □

By end user, the pharmaceutical & biotechnology companies segment acquired a high stake in the market in 2023. □

Region wise, North America was the highest revenue generator in 2023. □

Competition Analysis □

The major players of the global custom antibody services market □ are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies, Inc., Sino Biological, Inc., Bio-Rad Laboratories, Inc., Kaneka Eurogentec S.A., YenZym Antibodies, LLC., OriGene Technologies, Inc., Laboratory Corporation of America Holdings., and GenScript. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market. □

Additional benefits you will get with this purchase are:

- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free Data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

- Regulatory Guidelines
- Additional company profiles with specific to client's interest

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Service

- Antibody Development
- Antibody Production and Purification
- Antibody Fragmentation and Labeling

By Type

- Monoclonal Antibodies
- Polyclonal Antibodies
- Recombinant Antibodies
- Others

By Source

- Mice
- Rabbit
- Others

By Application

- Oncology
- Infectious Diseases
- Neurology
- Immunology
- Cardiovascular Diseases
- Others

By End User

- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Others

By Region

- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Agilent Technologies, Inc.
- Sino Biological, Inc.
- Bio-Rad Laboratories, Inc
- Kaneka Eurogentec S.A.
- YenZym Antibodies, LLC.
- OriGene Technologies, Inc.[]
- Laboratory Corporation of America Holdings.
- GenScript

Table of Contents:

CHAPTER 1: INTRODUCTION

- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
 - 1.4.1. Primary Research
 - 1.4.2. Secondary Research
 - 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

- 3.1. Market Definition and Scope
- 3.2. Key Findings
 - 3.2.1. Top Investment Pockets
 - 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
 - 3.3.1. Bargaining Power of Suppliers
 - 3.3.2. Threat of New Entrants
 - 3.3.3. Threat of Substitutes
 - 3.3.4. Competitive Rivalry
 - 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
 - 3.4.1. Drivers
 - 3.4.2. Restraints
 - 3.4.3. Opportunities

CHAPTER 4: CYTOTOXIC DRUG MARKET, BY DRUG TYPE

- 4.1. Market Overview
 - 4.1.1 Market Size and Forecast, By Drug Type

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.2. Alkylating Agents
 - 4.2.1. Key Market Trends, Growth Factors and Opportunities
 - 4.2.2. Market Size and Forecast, By Region
 - 4.2.3. Market Share Analysis, By Country
- 4.3. Antitumor Antibiotics
 - 4.3.1. Key Market Trends, Growth Factors and Opportunities
 - 4.3.2. Market Size and Forecast, By Region
 - 4.3.3. Market Share Analysis, By Country
- 4.4. Antimetabolites
 - 4.4.1. Key Market Trends, Growth Factors and Opportunities
 - 4.4.2. Market Size and Forecast, By Region
 - 4.4.3. Market Share Analysis, By Country
- 4.5. Plant Alkaloids
 - 4.5.1. Key Market Trends, Growth Factors and Opportunities
 - 4.5.2. Market Size and Forecast, By Region
 - 4.5.3. Market Share Analysis, By Country
- 4.6. Others
 - 4.6.1. Key Market Trends, Growth Factors and Opportunities
 - 4.6.2. Market Size and Forecast, By Region
 - 4.6.3. Market Share Analysis, By Country
- CHAPTER 5: CYTOTOXIC DRUG MARKET, BY APPLICATION
 - 5.1. Market Overview
 - 5.1.1 Market Size and Forecast, By Application
 - 5.2. Breast Cancer
 - 5.2.1. Key Market Trends, Growth Factors and Opportunities
 - 5.2.2. Market Size and Forecast, By Region
 - 5.2.3. Market Share Analysis, By Country
 - 5.3. Prostate Cancer
 - 5.3.1. Key Market Trends, Growth Factors and Opportunities
 - 5.3.2. Market Size and Forecast, By Region
 - 5.3.3. Market Share Analysis, By Country
 - 5.4. Lung Cancer
 - 5.4.1. Key Market Trends, Growth Factors and Opportunities
 - 5.4.2. Market Size and Forecast, By Region
 - 5.4.3. Market Share Analysis, By Country
 - 5.5. Pancreatic Cancer
 - 5.5.1. Key Market Trends, Growth Factors and Opportunities
 - 5.5.2. Market Size and Forecast, By Region
 - 5.5.3. Market Share Analysis, By Country
 - 5.6. Others
 - 5.6.1. Key Market Trends, Growth Factors and Opportunities
 - 5.6.2. Market Size and Forecast, By Region
 - 5.6.3. Market Share Analysis, By Country
- CHAPTER 6: CYTOTOXIC DRUG MARKET, BY ROUTE OF ADMINISTRATION
 - 6.1. Market Overview
 - 6.1.1 Market Size and Forecast, By Route of Administration
 - 6.2. Oral

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Parenteral
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- CHAPTER 7: CYTOTOXIC DRUG MARKET, BY DISTRIBUTION CHANNEL
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Distribution Channel
- 7.2. Hospital Pharmacies
- 7.2.1. Key Market Trends, Growth Factors and Opportunities
- 7.2.2. Market Size and Forecast, By Region
- 7.2.3. Market Share Analysis, By Country
- 7.3. Drug Stores And Retail Pharmacies
- 7.3.1. Key Market Trends, Growth Factors and Opportunities
- 7.3.2. Market Size and Forecast, By Region
- 7.3.3. Market Share Analysis, By Country
- 7.4. Online Providers
- 7.4.1. Key Market Trends, Growth Factors and Opportunities
- 7.4.2. Market Size and Forecast, By Region
- 7.4.3. Market Share Analysis, By Country
- CHAPTER 8: CYTOTOXIC DRUG MARKET, BY REGION
- 8.1. Market Overview
- 8.1.1 Market Size and Forecast, By Region
- 8.2. North America
- 8.2.1. Key Market Trends and Opportunities
- 8.2.2. Market Size and Forecast, By Drug Type
- 8.2.3. Market Size and Forecast, By Application
- 8.2.4. Market Size and Forecast, By Route of Administration
- 8.2.5. Market Size and Forecast, By Distribution Channel
- 8.2.6. Market Size and Forecast, By Country
- 8.2.7. U.S. Cytotoxic Drug Market
- 8.2.7.1. Market Size and Forecast, By Drug Type
- 8.2.7.2. Market Size and Forecast, By Application
- 8.2.7.3. Market Size and Forecast, By Route of Administration
- 8.2.7.4. Market Size and Forecast, By Distribution Channel
- 8.2.8. Canada Cytotoxic Drug Market
- 8.2.8.1. Market Size and Forecast, By Drug Type
- 8.2.8.2. Market Size and Forecast, By Application
- 8.2.8.3. Market Size and Forecast, By Route of Administration
- 8.2.8.4. Market Size and Forecast, By Distribution Channel
- 8.2.9. Mexico Cytotoxic Drug Market
- 8.2.9.1. Market Size and Forecast, By Drug Type
- 8.2.9.2. Market Size and Forecast, By Application
- 8.2.9.3. Market Size and Forecast, By Route of Administration
- 8.2.9.4. Market Size and Forecast, By Distribution Channel

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.3. Europe

8.3.1. Key Market Trends and Opportunities

8.3.2. Market Size and Forecast, By Drug Type

8.3.3. Market Size and Forecast, By Application

8.3.4. Market Size and Forecast, By Route of Administration

8.3.5. Market Size and Forecast, By Distribution Channel

8.3.6. Market Size and Forecast, By Country

8.3.7. Germany Cytotoxic Drug Market

8.3.7.1. Market Size and Forecast, By Drug Type

8.3.7.2. Market Size and Forecast, By Application

8.3.7.3. Market Size and Forecast, By Route of Administration

8.3.7.4. Market Size and Forecast, By Distribution Channel

8.3.8. France Cytotoxic Drug Market

8.3.8.1. Market Size and Forecast, By Drug Type

8.3.8.2. Market Size and Forecast, By Application

8.3.8.3. Market Size and Forecast, By Route of Administration

8.3.8.4. Market Size and Forecast, By Distribution Channel

8.3.9. UK Cytotoxic Drug Market

8.3.9.1. Market Size and Forecast, By Drug Type

8.3.9.2. Market Size and Forecast, By Application

8.3.9.3. Market Size and Forecast, By Route of Administration

8.3.9.4. Market Size and Forecast, By Distribution Channel

8.3.10. Italy Cytotoxic Drug Market

8.3.10.1. Market Size and Forecast, By Drug Type

8.3.10.2. Market Size and Forecast, By Application

8.3.10.3. Market Size and Forecast, By Route of Administration

8.3.10.4. Market Size and Forecast, By Distribution Channel

8.3.11. Spain Cytotoxic Drug Market

8.3.11.1. Market Size and Forecast, By Drug Type

8.3.11.2. Market Size and Forecast, By Application

8.3.11.3. Market Size and Forecast, By Route of Administration

8.3.11.4. Market Size and Forecast, By Distribution Channel

8.3.12. Rest of Europe Cytotoxic Drug Market

8.3.12.1. Market Size and Forecast, By Drug Type

8.3.12.2. Market Size and Forecast, By Application

8.3.12.3. Market Size and Forecast, By Route of Administration

8.3.12.4. Market Size and Forecast, By Distribution Channel

8.4. Asia-Pacific

8.4.1. Key Market Trends and Opportunities

8.4.2. Market Size and Forecast, By Drug Type

8.4.3. Market Size and Forecast, By Application

8.4.4. Market Size and Forecast, By Route of Administration

8.4.5. Market Size and Forecast, By Distribution Channel

8.4.6. Market Size and Forecast, By Country

8.4.7. Japan Cytotoxic Drug Market

8.4.7.1. Market Size and Forecast, By Drug Type

8.4.7.2. Market Size and Forecast, By Application

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.4.7.3. Market Size and Forecast, By Route of Administration
- 8.4.7.4. Market Size and Forecast, By Distribution Channel
- 8.4.8. China Cytotoxic Drug Market
 - 8.4.8.1. Market Size and Forecast, By Drug Type
 - 8.4.8.2. Market Size and Forecast, By Application
 - 8.4.8.3. Market Size and Forecast, By Route of Administration
 - 8.4.8.4. Market Size and Forecast, By Distribution Channel
- 8.4.9. India Cytotoxic Drug Market
 - 8.4.9.1. Market Size and Forecast, By Drug Type
 - 8.4.9.2. Market Size and Forecast, By Application
 - 8.4.9.3. Market Size and Forecast, By Route of Administration
 - 8.4.9.4. Market Size and Forecast, By Distribution Channel
- 8.4.10. Australia Cytotoxic Drug Market
 - 8.4.10.1. Market Size and Forecast, By Drug Type
 - 8.4.10.2. Market Size and Forecast, By Application
 - 8.4.10.3. Market Size and Forecast, By Route of Administration
 - 8.4.10.4. Market Size and Forecast, By Distribution Channel
- 8.4.11. South Korea Cytotoxic Drug Market
 - 8.4.11.1. Market Size and Forecast, By Drug Type
 - 8.4.11.2. Market Size and Forecast, By Application
 - 8.4.11.3. Market Size and Forecast, By Route of Administration
 - 8.4.11.4. Market Size and Forecast, By Distribution Channel
- 8.4.12. Rest of Asia-Pacific Cytotoxic Drug Market
 - 8.4.12.1. Market Size and Forecast, By Drug Type
 - 8.4.12.2. Market Size and Forecast, By Application
 - 8.4.12.3. Market Size and Forecast, By Route of Administration
 - 8.4.12.4. Market Size and Forecast, By Distribution Channel
- 8.5. LAMEA
 - 8.5.1. Key Market Trends and Opportunities
 - 8.5.2. Market Size and Forecast, By Drug Type
 - 8.5.3. Market Size and Forecast, By Application
 - 8.5.4. Market Size and Forecast, By Route of Administration
 - 8.5.5. Market Size and Forecast, By Distribution Channel
 - 8.5.6. Market Size and Forecast, By Country
 - 8.5.7. Brazil Cytotoxic Drug Market
 - 8.5.7.1. Market Size and Forecast, By Drug Type
 - 8.5.7.2. Market Size and Forecast, By Application
 - 8.5.7.3. Market Size and Forecast, By Route of Administration
 - 8.5.7.4. Market Size and Forecast, By Distribution Channel
 - 8.5.8. Saudi Arabia Cytotoxic Drug Market
 - 8.5.8.1. Market Size and Forecast, By Drug Type
 - 8.5.8.2. Market Size and Forecast, By Application
 - 8.5.8.3. Market Size and Forecast, By Route of Administration
 - 8.5.8.4. Market Size and Forecast, By Distribution Channel
 - 8.5.9. South Africa Cytotoxic Drug Market
 - 8.5.9.1. Market Size and Forecast, By Drug Type
 - 8.5.9.2. Market Size and Forecast, By Application

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.5.9.3. Market Size and Forecast, By Route of Administration
- 8.5.9.4. Market Size and Forecast, By Distribution Channel
- 8.5.10. Rest of LAMEA Cytotoxic Drug Market
 - 8.5.10.1. Market Size and Forecast, By Drug Type
 - 8.5.10.2. Market Size and Forecast, By Application
 - 8.5.10.3. Market Size and Forecast, By Route of Administration
 - 8.5.10.4. Market Size and Forecast, By Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

- 9.1. Introduction
- 9.2. Top Winning Strategies
- 9.3. Product Mapping of Top 10 Player
- 9.4. Competitive Dashboard
- 9.5. Competitive Heatmap
- 9.6. Top Player Positioning, 2023

CHAPTER 10: COMPANY PROFILES

- 10.1. Baxter
 - 10.1.1. Company Overview
 - 10.1.2. Key Executives
 - 10.1.3. Company Snapshot
 - 10.1.4. Operating Business Segments
 - 10.1.5. Product Portfolio
 - 10.1.6. Business Performance
 - 10.1.7. Key Strategic Moves and Developments
- 10.2. Cipla Ltd
 - 10.2.1. Company Overview
 - 10.2.2. Key Executives
 - 10.2.3. Company Snapshot
 - 10.2.4. Operating Business Segments
 - 10.2.5. Product Portfolio
 - 10.2.6. Business Performance
 - 10.2.7. Key Strategic Moves and Developments
- 10.3. Eli Lilly And Company
 - 10.3.1. Company Overview
 - 10.3.2. Key Executives
 - 10.3.3. Company Snapshot
 - 10.3.4. Operating Business Segments
 - 10.3.5. Product Portfolio
 - 10.3.6. Business Performance
 - 10.3.7. Key Strategic Moves and Developments
- 10.4. Fresenius Kabi AG
 - 10.4.1. Company Overview
 - 10.4.2. Key Executives
 - 10.4.3. Company Snapshot
 - 10.4.4. Operating Business Segments
 - 10.4.5. Product Portfolio
 - 10.4.6. Business Performance
 - 10.4.7. Key Strategic Moves and Developments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.5. Johnson And Johnson
 - 10.5.1. Company Overview
 - 10.5.2. Key Executives
 - 10.5.3. Company Snapshot
 - 10.5.4. Operating Business Segments
 - 10.5.5. Product Portfolio
 - 10.5.6. Business Performance
 - 10.5.7. Key Strategic Moves and Developments
- 10.6. Novartis AG
 - 10.6.1. Company Overview
 - 10.6.2. Key Executives
 - 10.6.3. Company Snapshot
 - 10.6.4. Operating Business Segments
 - 10.6.5. Product Portfolio
 - 10.6.6. Business Performance
 - 10.6.7. Key Strategic Moves and Developments
- 10.7. Viatris Inc.
 - 10.7.1. Company Overview
 - 10.7.2. Key Executives
 - 10.7.3. Company Snapshot
 - 10.7.4. Operating Business Segments
 - 10.7.5. Product Portfolio
 - 10.7.6. Business Performance
 - 10.7.7. Key Strategic Moves and Developments
- 10.8. Pfizer Inc.
 - 10.8.1. Company Overview
 - 10.8.2. Key Executives
 - 10.8.3. Company Snapshot
 - 10.8.4. Operating Business Segments
 - 10.8.5. Product Portfolio
 - 10.8.6. Business Performance
 - 10.8.7. Key Strategic Moves and Developments
- 10.9. Sun Pharmaceutical Industries Ltd.
 - 10.9.1. Company Overview
 - 10.9.2. Key Executives
 - 10.9.3. Company Snapshot
 - 10.9.4. Operating Business Segments
 - 10.9.5. Product Portfolio
 - 10.9.6. Business Performance
 - 10.9.7. Key Strategic Moves and Developments
- 10.10. Teva Pharmaceutical Industries Ltd.
 - 10.10.1. Company Overview
 - 10.10.2. Key Executives
 - 10.10.3. Company Snapshot
 - 10.10.4. Operating Business Segments
 - 10.10.5. Product Portfolio
 - 10.10.6. Business Performance

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.10.7. Key Strategic Moves and Developments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Custom Antibody Services Market? By Service (Antibody Development, Antibody Production and Purification, Antibody Fragmentation and Labeling) , By Type (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Antibodies, Others) By Source (Mice, Rabbit, Others) By Application (Oncology, Infectious Diseases, Neurology, Immunology, Cardiovascular Diseases, Others) By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Market Report | 2024-07-01 | 233 pages | Allied Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Cloud Access License	\$2389.50
	Business User License	\$5157.00
	Enterprise License	\$6670.80
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*

Phone*

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-05"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com